Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group's Stiripentol Dry Suspension has completed its renewal in the National Reimbursement Drug List (the "NRDL") (2026 Version) of China, and continues to be included in the new version of the NRDL.

The Group's Stiripentol Dry Suspension (two specifications of 250mg and 500mg) was approved in 2023, being the first approved generic Stiripentol dry suspension in China. This product was included in the NRDL in 2024. This product is a drug for rare disease that meets the physiological characteristics of children, and is mainly used for the treatment of Severe Myoclonic Epilepsy of Infancy (Dravet syndrome). Dravet syndrome is recognized by the International League Against Epilepsy as one of the epilepsy types with poor prognosis, and was included in the first batch of rare diseases list of China in 2018. Prior to the approval of this product, there was a lack of targeted treatment drugs in clinical practice, and traditional anti-epileptic regimens were insufficient to meet treatment needs. Children with Dravet syndrome require long-term and standardised treatment. This product's dosage form is suitable for young children with swallowing difficulties, addressing both medication adherence and individualised treatment needs. Also, the Group's Stiripentol bulk drug has been approved to become a bulk drug for the preparations on the market, forming a layout of integration of "Bulk Pharmaceuticals + Preparations" and ensuring cost control.

In recent years, the Group has focused on clinical pain points of pediatric drugs such as insufficient matching of dosage forms and specifications, and difficulty in achieving individually precise dosing. The Group has continuously expanded its research and development layout in pediatric-appropriate formulations, focusing on developing dosage forms suitable for children such as dry suspensions, oral solutions and granules, to promote the upgrade of pediatric drugs. The Group continuously enriches its pediatric drug pipeline in the fields with strong pediatric clinical demand including anti-infectives, respiratory, digestive and nervous system, optimizing specification designs and tastes of the drugs, and improving their safety and adherence. At the same time, the Group has been actively engaged in negotiations for national medical insurance coverage and policies of centralised procurement, striving for more clinically needed and pediatric-appropriate drugs to benefit patients and reduce their burden.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 16 November 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.